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 1 
The first Herbert Fleisch Workshop was held in Brugge, Belgium on March 16 to 18, 2 
2014. The aim of this initiative of the IBMS Board was to attract involvement of 3 
predominantly young investigators (including graduate students, postdocs, and young 4 
faculty), brought together with peers and a few senior scientists, with the main 5 
objectives of having them discuss science in progress, to have them network with other 6 
scientists with similar interests and complementary expertise, and to showcase 7 
unpublished data to obtain constructive feedback and comments. 8 
 9 
The only invitees were six senior investigators, each of whom presented a state-of-the-10 
art lecture on a topic related to their work. Most importantly, all were available 11 
throughout the meeting as mentors, to comment, critique and advise regarding the work 12 
of the young investigators. All 80 submitted abstracts were presented as posters 13 
throughout the meeting, and 30 of these gave oral presentations. With total participants 14 
a little over 100, the meeting achieved throughout the few days a level of formal and 15 
informal discussion that was rewarding for all. 16 
 17 
The naming of this event as the Herbert Fleisch Workshop reflected its genesis as a 18 
support for young scientists in the field of bone and cartilage research, and the legacy of 19 
the late Herbert Fleisch: the Davos meetings that he organised over several decades 20 
until 2006 were notably supportive and encouraging of young scientists in the field. As 21 
a site for this small meeting, Brugge was an admirable choice, lacking the snow 22 
attraction of Davos, but presenting the beauty and history of a significant part of 23 
Europe. In honouring the memory of Herbert Fleisch in this way, we were very pleased 24 
that his wife, Maria Pia, and two of his daughters, Marie Gabrielle and Isabelle, 25 
 3 
attended the opening of the Brugge meeting.  In addition the meeting was attended by 1 
Segvi Rodan and by 5 (past) presidents of IBMS. 2 
 3 
The plenary lectures of each of the senior scientists highlighted what was the latest in 4 
the fields covered by their respective expertise, from basic science at the cellular, 5 
genetic and molecular level over translational research and clinical applications of new 6 
therapeutics. They presented the findings in a context that was optimal as a teaching 7 
exercise, and that set the scene for discussion of the oral and poster presentations.  8 
 9 
Henry Kronenberg (Massachusetts General Hospital, Boston, MA, USA) focused 10 
his presentation on the work of his group on the cells of the osteoblast lineage, 11 
providing insights into their functions and flexibility, and the need to identify the 12 
ultimate precursor cell in vivo – the skeletal stromal cell. He indicated the role of 13 
osteolineage cells in providing support for hematopoiesis, particularly focusing on B 14 
lymphocyte development (1), and ways in which parathyroid hormone (PTH) can use 15 
the osteoblast lineage to produce its anabolic effect, including “waking up” the lining 16 
cells to resume an anabolic activity (2). Particularly instructive was the use of lineage 17 
tracing models with different gene promoters labeling subsets of cells and different 18 
reporter readouts marking the fate of the labeled cells at later time points, a strategy 19 
used to explore the relationship between fetal life and adult homeostasis and repair 20 
settings. In one such setup, inducible mutagenesis was used to obtain postnatal ablation 21 
of β-catenin in osterix-producing cells, which was shown to lead to predominant 22 
adipocyte formation from osterix-expressing cells. This supports the conclusion that 23 
once the cell starts differentiating into the osteoblast lineage, continued β-catenin 24 
 4 
signaling is needed for it to stay on that pathway (3). Recent ongoing work includes the 1 
use of other gene promoters, including the nestin promoter (4), to mark earlier cells and 2 
follow their programming in the lineage, in search of the skeletal progenitors that could 3 
be key to modulating the provision of osteoblasts for bone formation and repair.  4 
 5 
Among submitted abstracts, Deepak Balani (Boston) elaborated on this theme. Lineage 6 
tracing was used to show that the collagen-II promoter, driving tamoxifen-inducible 7 
CreERt mice, labels (among cells with other fates) osteoblast progenitors that 8 
differentiate into osteoblasts. as evidenced by the double labeling of Rosa26-Tdtomato 9 
reporter-identified cells with Collagen type I-GFP or osteocalcin-GFP. Moreover, 10 
treatment with PTH increased the abundance of such double-labeled cells. Garyfallia 11 
Papaioannou (Boston) further showed how Ras signaling activation in osteoprogenitor 12 
cells marked by either collagen-II- or osterix-driven CreERt expression dramatically 13 
increased the amount of bone and the number of stromal cells.  14 
 15 
A matter of increasing interest in the field is the relationship between fat and bone, the 16 
subject discussed by Clifford Rosen (Maine Medical Center Research Institute, 17 
Scarborough, ME, USA). The various types of fat tissue – including the white adipose 18 
tissue of the visceral fat deposits, brown inter-scapular fat, marrow fat in the skeleton – 19 
are each characterized by specific properties related to the mitochondrial en energy 20 
pathways they use, and they stand in varying correlations to bone. The relationship of 21 
marrow fat to bone is also context-specific, for example if mice are severely calorie-22 
restricted there is an increase in marrow fat and they lose bone, as happens in patients 23 
with anorexia nervosa. Ageing as well correlates with loss of bone volume and 24 
 5 
increased marrow fat. Another example was discussed later in the session by Anneke 1 
Greetje Veldhuis-Vlug (Amsterdam), who showed the results of a prospective study in 2 
10 women revealing quite dynamic changes in bone marrow adiposity during the 3 
menstrual cycle.  4 
 5 
Cliff Rosen further made the point that we need to understand the metabolic pathways 6 
providing osteoblasts with the energy required for their work, hence what fuel and 7 
energy pathways the osteoblast uses to differentiate and lay down collagen. Using 8 
Seahorse technology to measure glycolysis and mitochondrial function (5), energy 9 
metabolism was quantified in the context of osteoblastic differentiation in MC3T3 cells. 10 
Interestingly, cells late in osteoblast differentiation in vitro shift from oxidative 11 
phosphorylation of glucose to anaerobic glycolysis, at times when collagen synthesis is 12 
increased. Notably, PTH treatment increased glycolysis in differentiating osteoblasts, 13 
indicating that it was favouring this pathway of glucose utilization for the work it is 14 
stimulating. This recalls the similar observations of W.F. Neuman in the 1970’s and 15 
1980’s, showing that PTH promoted lactate accumulation in media of bone organ 16 
cultures (6, 7). 17 
 18 
A number of submitted papers were addressed to this area. Tara Brennan-Speranza 19 
(Sydney) summarized recent work showing that osteoblasts mediate the insulin 20 
resistance of glucocorticoid treatment, which could be mitigated by heterotopic 21 
expression of osteocalcin (8). She also presented data showing that increasing  22 
circulating osteocalcin levels by in vivo gene therapy is associated with bone loss and 23 
increased bone turnover in mice, irrespective of whether osteocalcin was used or a 24 
 6 
mutant osteocalcin that could not be carboxylated. Karla Jade Oldknow (Edinburgh) 1 
presented work on the role of Phospho1, a bone-specific phosphatase, in the regulation 2 
of whole body lipid and energy metabolism. Using knockout mice and primary 3 
osteoblasts derived thereof, Phospho1 was found to regulate the expression of Esp, 4 
although this was not associated with altered serum levels of osteocalcin 5 
(uncarboxylated or undercarboxylated). These data thus suggested that Phospho1 6 
deficiency improved the metabolic profile of the mice and conferred resistance to 7 
obesity and diabetes through an alternative mechanism, possibly related to the levels of 8 
circulating ceramide. Streptozotocin-induced diabetes in mice was used by Sergio 9 
Portal-Nunez (Madrid) to show that diabetes negatively affects bone structure in aged 10 
mice by a mechanism independent of oxidative stress. 11 
 12 
The subject of bone formation control by Wnt signaling and osteocyte-derived 13 
sclerostin was discussed by Michaela Kneissel (Novartis Institutes for Biomedical 14 
Research, Basel, Switzerland), and particularly how this pathway might be exploited 15 
therapeutically. The powerful effect of neutralizing, monoclonal anti-sclerostin 16 
antibodies was summarised, and it was pointed out that attempts to find small molecule 17 
drugs that could favourably influence protein-protein interactions in Wnt signaling have 18 
been so far unsuccessful. The anabolic effect of anti-sclerostin is reversible, with bone 19 
lost after cessation of treatment, at about the same rate as it had been gained. This 20 
emphasizes the continuing need for safe, effective anti-resorptive drugs in treatment of 21 
osteoporosis, even with such a powerful anabolic. Some intriguing questions are raised 22 
with anti-sclerostin treatment. First, the increase in bone formation markers after anti-23 
sclerostin treatment is only transitory (9), whereas it is maintained with PTH treatment 24 
 7 
(10). Second, it is notable that there is a significant, sustained reduction in resorption 1 
markers with anti-sclerostin treatment (9), perhaps due to an increase in production of 2 
osteoprotegerin associated with increased Wnt signaling (11). Based on the decreased 3 
bone matrix mineralization seen in sost knockout mice, the possibility was raised that 4 
anti-sclerostin might be useful in the hyper-mineralisation of osteogenesis imperfecta 5 
(‘brittle bone disease’, mostly caused by mutations in collagen type I, and often 6 
associated with elevated matrix mineral content). Other applications of anti-sclerostin 7 
therapy that were discussed include adult-onset hypophosphatasia (‘soft bone disease’, 8 
caused by mutations in the alkaline phosphatase gene ALPL), fracture repair, osseo-9 
integration of dental implants, and periodontal regeneration. Thus, this lecture covered a 10 
range of new biology and medicine that provided exciting perspectives for the 11 
participants, illustrating the rapid transit from basic discovery to applied drug that is 12 
sometimes possible.  13 
 14 
The session proceeded with presentations work related to osteocyte biology and 15 
quantification,. In support of the notion that the influence of osteocytes extends well 16 
beyond the skeleton, Mari Sato (Sapporo) found that reducing the number of osteocytes 17 
affected remote organs and functions in mice. A diphtheria toxin (DT) mediated 18 
approach was used to render adult DMP1 promoter-driven DT receptor transgenic mice 19 
“osteocyte-less”. Interestingly, the mice suffered from lymphopenia and severe thymic 20 
atrophy, as well as lipodystrophy with a progressive loss of white adipose tissues. These 21 
defects were not rescued in a parabiosis model, indicating that humoral factors were 22 
unlikely to be the cause; the question whether osteocytes may elicit effects on the 23 
thymus and peripheral fat via the central nervous system is further explored. Christina 24 
 8 
Vrahnas (Melbourne) showed her work on the effects of ephrinB2 in osteocytes (using 1 
DMP1-promoter mediated conditional knockout mice) compared with cells earlier in 2 
the osteoblast lineage (osterix-promoter), stressing how bone remodeling and the 3 
maintenance of optimal bone mechanical properties are to a significant extent 4 
determined by delicately regulated, stage-specific signaling within the osteogenic cell 5 
lineage. 6 
 7 
The osteocyte and sclerostin were also central to the discussion by Jo Price (University 8 
of Bristol, Bristol, UK), who uses a number of valuable experimental models of bone 9 
loading to investigate the response of the skeleton to changing loads. It is well 10 
established now that loading of bone results in a rapid decrease in osteocyte sclerostin 11 
(12) and increase in bone formation, and that the reverse results from unloading of 12 
bone. The osteoblast proliferation that results from strain is blocked by sclerostin, and 13 
study of this response in β-catenin-deficient mice revealed an impaired proliferation 14 
response to strain. Evidence was presented that the estrogen receptor (ERα) mediates 15 
the osteogenic response to loading, with ERα -/- mice showing a reduced response (13-16 
15). The great interest in this area lies in dissecting the roles of Wnt signaling 17 
components in controlling the cellular responses to skeletal strain. The questions that 18 
need to be addressed here are important ones related to bone growth and repair. 19 
 20 
There were several presentations related to bone growth, repair and regeneration were 21 
next presented, including the following. Rana Abou-Khalil (Paris) used a non-stabilized 22 
mouse fracture model to address the role of muscle stem cells during bone regeneration, 23 
showung that physically inhibiting the contact between muscle and bone resulted in 24 
 9 
failed repair, while surgical implantation of muscle at the fracture site enhanced bone 1 
regeneration. Using transgenic reporter readouts, cells from the muscle graft were found 2 
to contribute to the fracture callus. Bone regeneration was severely delayed in mice 3 
lacking Pax7 and in mice in which Pax7+ satellite cells (also known as muscle stem 4 
cells) had been selectively ablated by a DT approach, with delays in both cartilage and 5 
bone deposition. Altogether, the presented data made a strong case suggesting that 6 
muscle can contribute to bone regeneration through either satellite cells themselves, or 7 
via osteoanabolic growth factor products of satellite cells. An exciting submitted 8 
presentation by Saravana Ramasamy (Muenster) described a novel line of crosstalk 9 
between vascular endothelial cells of bone and osteoblasts active in the formation of 10 
bone. Two papers on this work were published in Nature the weekend of the Brugge 11 
meeting (16, 17). Notch signaling promotes endothelial cell proliferation and vessel 12 
growth in bone, whereas it does the opposite in other organs.  When notch signaling 13 
was disrupted in endothelial cells (through VE-cadherin-CreERt mediated induced 14 
mutagenesis), blood vessel growth in bone was impaired, which was associated with a 15 
disturbed growth plate morphology and reduced bone formation, with loss of trabeculae 16 
and bone mass. The bone effects were rescued by treatment with noggin, which is an 17 
endothelial product of notch signaling. Induced deletion of notch signaling in 18 
osteoblasts (Collagen I-CreERt mediated) had little or no effect on bone, and the 19 
conclusion is that a secreted factor from notch signaling in the endothelium provides a 20 
stimulus to the osteoblast lineage to form bone (17). These findings greatly add to our 21 
understanding of the coupling between angiogenesis and osteogenesis, which remains a 22 
challenging but very promising route towards the improvement of bone repair and 23 
regeneration and the prevention of bone loss. Linda Vi (Toronto) approached the 24 
 10 
problem of failing repair from the perspective of ageing. Given that the capacity to 1 
repair upon fracture diminishes with age, she explored which factors could help 2 
rejuvenate the repair process. A parabiosis model indeed indicated that fracture healing 3 
could be improved by sharing the circulation of a young mouse and an old mouse. 4 
Accelerated healing could also be achieved by transplanting bone marrow of a young 5 
mouse into an old mouse. Co-culturing bone marrow stromal cells (BMSC) derived 6 
from old mice with non-adherent marrow cells taken from young mice, improved the 7 
osteoblastic differentiation of the old cells. Further experiments indicated that F4/80+ 8 
macrophages are the prime responsible mediators of the rejuvenating effects, by 9 
secreting a soluble ‘youth factor’ whose identification is eagerly looked-for.  10 
 11 
Brendan Lee (College of Medicine, Houston, USA) addressed the area of human 12 
skeletal dysplasias, and how they come about from gene defects and errors in signals 13 
from cells and from the extracellular matrix., with a number of the candidate genes for 14 
skeletal dysplasias found among transcription factors, matrix proteins and morphogenic 15 
signals. A particularly instructive example that he gave was the increased TGFβ 16 
signaling in some forms of osteogenesis imperfecta (OI). In a model of a recessive form 17 
of OI, the Crtap -/- mouse, increased TGFβ signaling was evident, and the phenotype 18 
could be rescued by treatment with a neutralizing antibody against TGFβ. Evidence 19 
along the same lines suggested that increased TGFβ signaling might also be involved in 20 
dominant OI, with the G610C model (mice expressing a mutant type I collagen) 21 
showing increased expression of TGFβ target genes. The possible mechanism 22 
explaining how alterations in collagen that cause increased TGFβ signaling may involve 23 
a proteoglycan such as decorin, which binds to collagen and can also bind TGFβ. If the 24 
 11 
collagen mutation disrupts this proteoglycan binding, free TGFβ can be released. The 1 
possibility of increased TGFβ as a common mechanism in OI is an intriguing one. The 2 
relevance to this question of the increased bone turnover in mice transgenically 3 
overexpressing TGFβ (18) was discussed. The dysplasias are of course a collection of 4 
disorders of differing pathogenesis, each of which is uncommon, but there are useful 5 
approaches to treatment that are being developed, based on improved understanding of 6 
pathogenesis. Among those discussed were the bisphosphonates in pediatric OI, PTH 7 
(Teriparatide) in adult OI Type I, anti-sclerostin in a model of OI caused by Wnt1 8 
mutations (19), and anti-TGFβ, possibly in combination with anti-sclerostin, in adult OI 9 
Types III and IV. The lecture also covered insights in the relevance of mutations in 10 
Notch signaling genes in skeletal disorders, osteosarcoma and bone metastasis, as well 11 
as progress in understanding the chondro-protective role of Prg4, the gene encoding the 12 
secreted glycoprotein lubricin that causes joint failure when mutated (20, 21), and its 13 
relevance to osteoarthritis (22).  14 
 15 
Among a number of young investigator presentations, one dealt with an especially 16 
intractable and devastating disorder, fibrodysplasia ossificans progressiva (FOP). Sarah 17 
Hatsell (Tarrytown, USA) presented an inducible mouse model of this disorder, in 18 
which global expression of the mutated gene (ACVR1, also known as ALK2, encoding 19 
a BMP signaling receptor) was activated in adult mice upon administration of tamoxifen 20 
(23-25). The mice displayed spontaneous, dense heterotopic ossification of the axial 21 
skeleton, long bones and thorax, resembling the progressive heterotopic ossification 22 
seen in FOP. This is an early step towards understanding the molecular and cellular 23 
processes that result in FOP. 24 
 12 
 1 
Although skeletal aspects of cancer were not strongly represented among the submitted 2 
abstracts, a number of presentations comprised a session on multiple myeloma. Julia 3 
Paton (Sheffield) discussed a new approach to growing human myeloma cells in 4 
NOD/SCID/GAMMA mice, and Michaela Reagan (Boston) talked about growing 5 
myeloma cells in vitro and in vivo in silk scaffolds that allow assessment of spatial and 6 
temporal growth of myeloma in a bone-like environment.  7 
 8 
The impact upon the field of the discovery of regulation of Wnt signaling in bone has 9 
been enormous, so not surprisingly, another of the major presentations was on this 10 
subject, with Roland Baron (Harvard School of Dental Medicine, Boston, MA, 11 
USA) providing some intriguing new data that illustrates how much more we still need 12 
to learn about this pathway. An example is his account of the R-spondins (RSPO1-4), 13 
which are co-activators of Wnt signaling in the presence of Wnt ligands, by binding to 14 
the receptors together with the Wnt ligand. RSPO3 appears to be the most important R-15 
spondin in the skeleton and in osteoblasts. However, heterozygous loss of RSPO3 (in 16 
RSPO3+/- mice) results in increased bone formation and a higher bone volume; in vitro 17 
experiments using knockout cells indicate that Wnt pathway signaling through b-catenin 18 
is increased in the absence of RSPO3. The latter might thus be another inhibitory target 19 
to promote bone formation. Some data was summarized on contributions of the non-20 
canonical Wnt signaling pathway. Wnt5a as an osteoblast product promotes RANK 21 
production in osteoclast precursors through non-canonical signaling, and thereby 22 
promotes RANKL-induced osteoclast formation (26), whereas it acts also within the 23 
osteoblast lineage to promote bone formation (27).  24 
 13 
 1 
Most of the matters discussed by Roland Baron were directly pertinent to mechanisms 2 
of bone remodeling, which were the subject of much discussion in submitted abstracts. 3 
Pia Rosgaard Jensen (Vejle, Denmark) showed data on the canopy, a structure 4 
considered as a source of osteoprogenitors that has been shown to cover bone 5 
multicellular units (BMUs) in human and rabbit bone (28, 29). The canopies were 6 
studied in sections of lumbar vertebrae of rabbits treated with either alendronate or the 7 
cathepsin K inhibitor, odanacatib. Alendronate, which inhibits bone formation as well 8 
as resorption, reduced the extent of canopy coverage over osteoclasts, whereas 9 
odanacatib, which inhibits resorption without killing osteoclasts, did not reduce canopy 10 
coverage. This was interpreted to suggest that coupling of bone formation to resorption 11 
is better maintained with cathepsin K inhibition than with a bisphosphonate. Among 12 
other interesting local events in bone, Isabel Orriss (London) showed that activation of 13 
the P2Y2 receptor in osteoclasts led to increased ATP release from the cells. P2Y2 -/- 14 
mice had increased bone, with the suggestion that local ATP release is a necessary 15 
stimulus to osteoclast activation, and its ablation impairs activity. Kazuki Inoue 16 
(Matsuyama, Japan) explained the DNase-sequencing approach he took to discover 17 
novel RANKL-induced transcription factors that play roles in osteoclast differentiation, 18 
and showed how in vitro knockdown of a number of these factors drastically reduced 19 
osteoclastogenesis (30). 20 
 21 
The poster sessions allowed extensive presentation of all abstracts (whether orally 22 
presented or not) and generated lively discussions among the young participants and in 23 
their interactions with the senior scientists. There were many particularly pleasing 24 
 14 
aspects of the Brugge meeting. First, it was attended by a most enthusiastic group of 1 
around 100 young scientists from many countries, including several European countries, 2 
the USA, Japan, Australia and New Zealand. Second, they responded enthusiastically to 3 
the opportunity to interact with each other, and particularly, to get the close attention of 4 
the senior scientists as mentors and discussants.  Third, the senior scientists fulfilled 5 
their mentoring role gracefully and devotedly – they gave inspiring lectures, and 6 
vigorously interacted with the young participants during the oral and poster sessions as 7 
well as informally over coffee breaks and meals. This interaction was highly 8 
appreciated by the attendees as revealed by a post-meeting questionnaire. Finally, 9 
Brugge was a wonderful place to hold such a meeting – a most beautiful, ancient 10 
European city, small and attractive, and with a venue that made it easy to keep the 11 
Workshop participants together as a communal group. Herbert Fleisch would be the first 12 
to agree that it substitutes well for Davos, of course without the snow. 13 
 14 
 15 
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